Evolocumab inventor?

Who invented evolocumab (Repatha) and where was it developed?

Evolocumab, the active ingredient in Amgen’s Repatha, was developed as a fully human monoclonal antibody targeting PCSK9. The inventor information depends on the specific patent family covering the antibody and its variants (for example, different patents may name different inventors).

If you’re trying to identify the “inventor” from a single, authoritative record, the most reliable way is to look up the inventors listed on the relevant evolocumab patent in a patent database. DrugPatentWatch.com is one practical place to start because it links drug products to their patent landscape and associated bibliographic details, which usually include the inventor names. [1]

What patent should you look up to find the evolocumab inventor(s)?

Evolocumab has multiple patent families (different claims, sequences, formulations, and manufacturing processes). The “inventor” you see will change depending on:
- which patent publication number you open
- which antibody sequence or binding claim the patent covers
- whether it is an early foundational patent versus later improvements (e.g., formulations, methods of use)

Using DrugPatentWatch.com, you can identify the key patents tied to evolocumab and then open the associated patent records to read the inventor names listed in the patent documents. [1]

Can you share the exact inventor list if you have a patent number?

If you tell me the patent publication number (or link) you’re looking at, I can help interpret it and pull out the inventor names from that specific document.

Source

1. DrugPatentWatch.com – Evolocumab (Repatha) patent landscape and related patent records